The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Charles Geyer
Honoraria - Merck; Tersera
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Genentech/Roche; Merck
 
Miguel Martin
Stock and Other Ownership Interests - AstraZeneca; Pfizer
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; ROVI Spain; STEMLINE-MENARINI
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - AstraZeneca; Novartis; Roche
 
Sara Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Stemline/Menarini (Inst); Zymeworks (Inst)
Other Relationship - BeiGene (Inst); BMS (Inst); Boehringer Ingelheim; Briacell (Inst); BridgeBio Pharma (Inst); Celcuity; Embiosys; Gilead Sciences (Inst); InClin/Atossa; Jazz Pharmaceuticals (Inst); Luminate (Inst); Medsir; Mersana (Inst); Novartis; Pfizer; Roche; Roche (Inst)
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bixink; Celgene; Daewoong Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Eisai; Everest Medicine; Gilead Sciences; ImmuneOncia; Merck; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Roche; Roche; Takeda
 
Mothaffar Rimawi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Novartis; Pfizer; Stemline Therapeutics; Tempus
Research Funding - Greenwich LifeSciences (Inst)
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Kyowa Kirin; Lilly; MSD; Myriad Genetics; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; Lilly; MSD; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Gustavo Werutsky
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; MSD; Novartis; Olema Oncology; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Libbs (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; IQVIA; Roche/Genentech; Springer; West German Study Group (I)
Speakers' Bureau - High5Oncology; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)
 
Sherene Loi
Honoraria - Adanate; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Ernesto Korbenfeld
Honoraria - AstraZeneca
Consulting or Advisory Role - PFIZER
 
Isabel Blancas
Honoraria - Adelphi Targis; AstraZeneca Spain; Bristol Myers Squibb; Cinfa; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Grunenthal; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; TACTICS; Transworld Editors; Veracyte; Veracyte
Consulting or Advisory Role - Adelphi Targis; AstraZeneca Spain; Cinfa; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Transworld Editors; Veracyte
Research Funding - Agendia (Inst); AstraZeneca Spain (Inst); Lilly; Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Other Relationship - Fundación San Juan de Dios; Medical Science Innovation Research (MEDSIR)
 
Chi-Feng Chung
Consulting or Advisory Role - AstraZeneca; Daichi Sankyo; EirGenix; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Rena Callahan
Honoraria - Curio Science; IDEOlogy Health; MJH Life Sciences
Consulting or Advisory Role - Arvinas; AstraZeneca/Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Roche/Genentech; Stemline Therapeutics
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Hologic/Biotheranostics; Lilly; Novartis; Stemline Therapeutics
Research Funding - Celcuity (Inst); Lilly (Inst); Roche/Genentech (Inst)
 
Meilin Huang
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Miranda Craft
Employment - Genetech, Inc
Stock and Other Ownership Interests - Roche
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Daniel Clyde, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Mona Shah
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
Research Funding - Roche
 
Tanja Badovinac Crnjevic
Employment - Roche
Stock and Other Ownership Interests - Roche
Honoraria - Roche
Patents, Royalties, Other Intellectual Property - Roche
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Daniel Clyde, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Pablo Pérez-Moreno
Employment - Genentech
Stock and Other Ownership Interests - F. Hoffmann LaRoche
Other Relationship - Support for third-party writing assistance for this abstract, furnished by Daniel Clyde, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Aditya Bardia
Consulting or Advisory Role - Alyssum; Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)